Role of Exosomes in Epithelial-Mesenchymal Transition.

Biomarkers Cancer EMT Exosome Metastasis Therapeutic

Journal

ACS applied bio materials
ISSN: 2576-6422
Titre abrégé: ACS Appl Bio Mater
Pays: United States
ID NLM: 101729147

Informations de publication

Date de publication:
18 Dec 2023
Historique:
medline: 18 12 2023
pubmed: 18 12 2023
entrez: 18 12 2023
Statut: aheadofprint

Résumé

Epithelial-mesenchymal transition (EMT) is a fundamental process driving cancer metastasis, transforming non-motile cells into a motile population that migrates to distant organs and forms secondary tumors. In recent years, cancer research has revealed a strong connection between exosomes and the EMT. Exosomes, a subpopulation of extracellular vesicles, facilitate cellular communication and dynamically regulate various aspects of cancer metastasis, including immune cell suppression, extracellular matrix remodeling, metastasis initiation, EMT initiation, and organ-specific metastasis. Tumor-derived exosomes (TEXs) and their molecular cargo, comprising proteins, lipids, nucleic acids, and carbohydrates, are essential components that promote EMT in cancer. TEXs miRNAs play a crucial role in reprogramming the tumor microenvironment, while TEX surface integrins contribute to organ-specific metastasis. Exosome-based cancer metastasis research offers a deeper understanding about cancer and an effective theranostic platform development. Additionally, various therapeutic sources of exosomes are paving the way for innovative cancer treatment development. In this Review, we spotlight the role of exosomes in EMT and their theranostic impact, aiming to inspire cancer researchers worldwide to explore this fascinating field in more innovative ways.

Identifiants

pubmed: 38108852
doi: 10.1021/acsabm.3c00941
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Bikramjit Bhattacharya (B)

Department of Applied Microbiology, School of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu 632014, India.

Sagnik Nag (S)

Department of Bio-Sciences, School of Bio-Sciences & Technology, Vellore Institute of Technology (VIT), Tiruvalam Road, Vellore, Tamil Nadu 632014, India.

Sayantanee Mukherjee (S)

Amrita School of NanoSciences and Molecular Medicine, Amrita Institute of Medical Sciences, Kochi, Kerala 682041, India.

Mrunal Kulkarni (M)

Department of Pharmacy, BITS Pilani, Pilani, Rajasthan 333031, India.

Priti Chandane (P)

Department of Biochemistry, University of Hyderabad, Hyderabad, Telangana 500046, India.

Debashmita Mandal (D)

Department of Biotechnology, Maulana Abul Kalam Azad University of Technology (MAKAUT), Haringhata, Nadia, West Bengal 741249, India.

Nobendu Mukerjee (N)

Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu 600077, India.
Department of Health Sciences, Novel Global Community and Educational Foundation, Hebersham, New South Wales 2770, Australia.

Divya Mirgh (D)

Vaccine and Immunotherapy Canter, Massachusetts General Hospital, Boston, Massachusetts 02114, United States.

Krishnan Anand (K)

Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein 9300, South Africa.

Manab Deb Adhikari (MD)

Department of Biotechnology, University of North Bengal Raja Rammohunpur, Darjeeling, West Bengal 734013, India.

Sukhamoy Gorai (S)

Rush University Medical Center, 1620 W. Harrison St., Chicago, Illinois 60612, United States.

Nanasaheb Thorat (N)

Limerick Digital Cancer Research Centre and Department of Physics, Bernal Institute, University of Limerick, Limerick V94T9PX, Ireland.

Classifications MeSH